Rubius Therapeutics Announces Preclinical Data for RTX-224, a Broad Immune Costimulatory Agonist, to be Presented at the Society for Immunotherapy of Cancer’s Annual Meeting
October 01 2021 - 8:00AM
Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage
biopharmaceutical company that is genetically engineering red blood
cells to create an entirely new class of cellular medicines called
Red Cell Therapeutics™ for the treatment of cancer and autoimmune
diseases, today announced it will present preclinical data for
RTX-224, a broad immune costimulatory agonist for the treatment of
cancer, at the upcoming Society for Immunotherapy of Cancer’s
(SITC) 36th Annual Meeting which is being held from November 10-14,
2021, in Washington, D.C., and virtually.
RTX-224 is an allogeneic cellular therapy that is engineered to
express hundreds of thousands of copies of 4-1BB ligand (4-1BBL)
and interleukin-12 (IL-12) on the cell surface. RTX-224 is designed
as a broad immune agonist of both adaptive and innate responses,
activating CD8+ and CD4+ T cells, promoting antigen presentation
and activating and expanding NK cells. It is expected to produce a
broad and potent anti-tumor T cell response, an innate immune
response and have anti-tumor activity in those tumor types with
known sensitivity to T cell killing, including tumor types with
high mutational burden, PD-L1 expression and prior responsiveness
to checkpoint inhibitors.
“At SITC, we plan to present preclinical data indicating that
RTX-224 activates immune cells in the spleen and blood, leading to
their trafficking into the tumor microenvironment to deliver an
anti-tumor effect in our preclinical models,” said Laurence Turka,
M.D., chief scientific officer of Rubius Therapeutics. “The
combination of IL-12 and 4-1BB ligand has the potential to broadly
induce an immune response in patients with solid tumors and may
serve as the bridge between the innate and adaptive immune systems.
These preclinical data are encouraging, and we plan to submit an
Investigational New Drug application to the FDA by year end.”
Details of the poster are as follows:
Poster Title: RTX-224, An Engineered Allogeneic
Red Cell Therapeutic Expressing 4-1BBL and IL-12, Activates Immune
Cells in Blood and Spleen to Promote Tumor Growth Inhibition in
MiceAbstract Number: 208 (ePoster)Date,
Time and Location: Friday, November 12, 2021, at 7 a.m.
EST through Sunday, November 14, 2021, at 5 p.m. EST on the SITC
website: www.sitcancer.org/2021
About Rubius TherapeuticsRubius Therapeutics is
a clinical-stage biopharmaceutical company developing a new class
of medicines called Red Cell Therapeutics™. The Company’s
proprietary RED PLATFORM® was designed to genetically engineer and
culture Red Cell Therapeutics™ that are selective, potent and
off-the-shelf allogeneic cellular therapies for the potential
treatment of several diseases across multiple therapeutic areas.
Rubius’ initial focus is to advance RCT™ product candidates for the
treatment of cancer and autoimmune diseases by leveraging two
distinct therapeutic modalities — potent cell-cell interaction and
tolerance induction. Rubius Therapeutics was named among the
2020 Top Places to Work in Massachusetts by the Boston Globe, and
its manufacturing site was recently named 2021 Best
Places to Work in Rhode Island by Providence Business News.
For more information, visit www.rubiustx.com, follow us on Twitter
or LinkedIn or like us on Facebook.
Forward Looking Statements This press release
contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995, as amended,
including, without limitation, statements regarding our
expectations with respect to the therapeutic potential of our
pipeline of Red Cell Therapeutics™, including RTX-224, analyses of
our preclinical data, including the impact of RTX-224 on certain
immune cells and anti-tumor effects, expectations for the potential
for IL-12 and 4-1BB ligand to broadly induce an immune response in
patients and act as a bridge between the innate and adaptive immune
systems and plans to submit an IND by year end. The words “may,”
“will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,”
“intend,” “believe,” “estimate,” “predict,” “project,” “potential,”
“continue,” “target” and similar expressions are intended to
identify forward-looking statements, although not all
forward-looking statements contain these identifying words. Any
forward-looking statements in this press release are based on
management’s current expectations and beliefs and are subject to a
number of risks, uncertainties and important factors that may cause
actual events or results to differ materially from those expressed
or implied by any forward-looking statements contained in this
press release, including, without limitation, those risks and
uncertainties related to the development of our Red Cell
Therapeutic product candidates, including RTX-224, and their
therapeutic potential and other risks identified in our filings
with the U.S. Securities and Exchange Commission (SEC), including
our Quarterly Report on Form 10-Q for the quarter ended June 30,
2021, and subsequent filings with the SEC. We caution you not to
place undue reliance on any forward-looking statements, which speak
only as of the date they are made. We disclaim any obligation to
publicly update or revise any such statements to reflect any change
in expectations or in events, conditions or circumstances on which
any such statements may be based, or that may affect the likelihood
that actual results will differ from those set forth in the
forward-looking statements. Any forward-looking statements
contained in this press release represent our views only as of the
date hereof and should not be relied upon as representing our views
as of any subsequent date. We explicitly disclaim any obligation to
update any forward-looking statements.
Contacts:
InvestorsElhan Webb, CFA, Vice President of
Investor Relationselhan.webb@rubiustx.com
Media Marissa Hanify, Director, Corporate
CommunicationsMarissa.hanify@rubiustx.com
Dan Budwick, 1AB+1 (973) 271-6085dan@1abmedia.com
Rubius Therapeutics (NASDAQ:RUBY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Rubius Therapeutics (NASDAQ:RUBY)
Historical Stock Chart
From Apr 2023 to Apr 2024